Outcomes of SMARCB1-deficient sinonasal carcinoma: Largest single-center cross-sectional study.
INI‐1
SMARCB‐1
induction chemotherapy
sinonasal carcinoma
skull base
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
23 Jul 2024
23 Jul 2024
Historique:
revised:
12
06
2024
received:
15
04
2024
accepted:
23
06
2024
medline:
24
7
2024
pubmed:
24
7
2024
entrez:
24
7
2024
Statut:
aheadofprint
Résumé
We evaluate outcomes of SMARCB1-deficient sinonasal carcinomas in the largest single-institution study. Retrospective cross-sectional study of patients with SMARCB1-deficient sinonasal carcinoma between 1998 and 2024. Disease-specific survival (DSS) and recurrence-free probability (RFP) at 1 and 5 years were measured by Kaplan-Meier method. There were 47 patients with a median age of 53. Initial pathological diagnosis was altered in 33%. Twelve (34%) patients received neoadjuvant chemotherapy, with one partial response. Curative surgical approach was undertaken in 73%. Definitive chemoradiation was administered in 20%. DSS at 1 and 5 years was 93% and 45%, respectively. RFP at 1 and 5 years was 73% and 33%, respectively. On multivariate analysis, cranial nerve involvement (p = 0.01 for DSS) remained significantly worse for DSS and overall survival. SMARCB1-deficient tumors had limited response to neoadjuvant chemotherapy. Cranial nerve involvement was associated with worse prognosis. Optimal treatment is unclear. Surgery should be offered to patients with resectable disease.
Sections du résumé
BACKGROUND
BACKGROUND
We evaluate outcomes of SMARCB1-deficient sinonasal carcinomas in the largest single-institution study.
METHODS
METHODS
Retrospective cross-sectional study of patients with SMARCB1-deficient sinonasal carcinoma between 1998 and 2024. Disease-specific survival (DSS) and recurrence-free probability (RFP) at 1 and 5 years were measured by Kaplan-Meier method.
RESULTS
RESULTS
There were 47 patients with a median age of 53. Initial pathological diagnosis was altered in 33%. Twelve (34%) patients received neoadjuvant chemotherapy, with one partial response. Curative surgical approach was undertaken in 73%. Definitive chemoradiation was administered in 20%. DSS at 1 and 5 years was 93% and 45%, respectively. RFP at 1 and 5 years was 73% and 33%, respectively. On multivariate analysis, cranial nerve involvement (p = 0.01 for DSS) remained significantly worse for DSS and overall survival.
CONCLUSIONS
CONCLUSIONS
SMARCB1-deficient tumors had limited response to neoadjuvant chemotherapy. Cranial nerve involvement was associated with worse prognosis. Optimal treatment is unclear. Surgery should be offered to patients with resectable disease.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Thompson LDR, Bishop JA. Update from the 5th edition of the World Health Organization classification of head and neck tumors: nasal cavity, paranasal sinuses and skull base. Head Neck Pathol. 2022;16(1):1‐18.
Lee VH, Tsang RK, Lo AWI, et al. SMARCB1 (INI‐1)‐deficient sinonasal carcinoma: a systematic review and pooled analysis of treatment outcomes. Cancers (Basel). 2022;14(13):3285.
Agaimy A, Hartmann A, Antonescu CR, et al. SMARCB1 (INI‐1)‐deficient sinonasal carcinoma: a series of 39 cases expanding the morphologic and clinicopathologic spectrum of a recently described entity. Am J Surg Pathol. 2017;41(4):458‐471.
Dogan S, Cotzia P, Ptashkin RN, et al. Genetic basis of SMARCB1 protein loss in 22 sinonasal carcinomas. Hum Pathol. 2020;104:105‐116.
Kezlarian BE, Lin O, Dogan S. SMARCB1‐deficient carcinomas of the head and neck region: a cytopathologic characterization. J Am Soc Cytopathol. 2020;9(6):494‐501.
Bell D, Hanna EY, Agaimy A, Weissferdt A. Reappraisal of sinonasal undifferentiated carcinoma: SMARCB1 (INI1)‐deficient sinonasal carcinoma: a single‐institution experience. Virchows Arch. 2015;467(6):649‐656.
Amit M, Abdelmeguid AS, Watcherporn T, et al. Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma. J Clin Oncol. 2019;37(6):504‐512.
Castelnuovo P, Lambertoni A, Sileo G, et al. Critical review of multidisciplinary approaches for managing sinonasal tumors with orbital involvement. Acta Otorhinolaryngol Ital. 2021;41(Suppl 1):S76‐S89.
Gomez‐Acevedo H, Patterson JD, Sardar S, et al. SMARC‐B1 deficient sinonasal carcinoma metastasis to the brain with next generation sequencing data: a case report of perineural invasion progressing to leptomeningeal invasion. BMC Cancer. 2019;19(1):827.
Jamshidi F, Pleasance E, Li Y, et al. Diagnostic value of next‐generation sequencing in an unusual sphenoid tumor. Oncologist. 2014;19(6):623‐630.
Amin MB, American Joint Committee on Cancer, American Cancer Society. In: Amin MB, Edge SB, Gress DM, Meyer LR, eds. AJCC Cancer Staging Manual. 8th ed. Chicago IL, Springer; 2017.
Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703‐713.
Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering‐integrated mutation profiling of actionable cancer targets (MSK‐IMPACT): a hybridization capture‐based next‐generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3):251‐264.
Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.
Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401‐404.
Choi KY, Amit M, Tam S, et al. Clinical implication of diagnostic and histopathologic discrepancies in sinonasal malignancies. Laryngoscope. 2021;131(5):E1468‐E1475.
Jurmeister P, Gloss S, Roller R, et al. DNA methylation‐based classification of sinonasal tumors. Nat Commun. 2022;13(1):7148.
Dogan S, Vasudevaraja V, Xu B, et al. DNA methylation‐based classification of sinonasal undifferentiated carcinoma. Mod Pathol. 2019;32(10):1447‐1459.
Contrera KJ, Shakibai N, Su SY, et al. Impact of clinical factors and treatments on SMARCB1 (INI‐1)‐deficient sinonasal carcinoma. Otolaryngol Head Neck Surg. 2023;169(2):435‐440.
Parsel SM, Jawad BA, McCoul ED. SMARCB1‐deficient sinonasal carcinoma: systematic review and case report. World Neurosurg. 2020;136:305‐310.
Cooper GW, Hong AL. SMARCB1‐deficient cancers: novel molecular insights and therapeutic vulnerabilities. Cancers (Basel). 2022;14(15):3645.
Gounder M, Schoffski P, Jones RL, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open‐label, phase 2 basket study. Lancet Oncol. 2020;21(11):1423‐1432.
Chi SN, Yi JS, Williams PM, et al. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI‐COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023;115(11):1355‐1363.
Laco J, Chmelarova M, Vosmikova H, et al. SMARCB1/INI1‐deficient sinonasal carcinoma shows methylation of RASSF1 gene: a clinicopathological, immunohistochemical and molecular genetic study of a recently described entity. Pathol Res Pract. 2017;213(2):133‐142.
Basyuni S, Nugent G, Ferro A, et al. Value of p53 sequencing in the prognostication of head and neck cancer: a systematic review and meta‐analysis. Sci Rep. 2022;12(1):20776.